返回排名列表

BGM Group Ltd. (BGM)

被高估
HealthcareDrug Manufacturers - Specialty & GenericChina

基本面

32

价格

$7.42

市值

$100M

第一部分 · 这家公司值多少

概览

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

Jinhe Biotechnology Co., Ltd. (金河生物科技股份有限公司)002688.SZ

Both are Chinese producers of tetracycline-class antibiotic active ingredients and premixes sold to the same livestock, poultry and feed customers at home and for export.

Ningxia Tairui Pharmaceutical Co., Ltd. (宁夏泰瑞制药股份有限公司)Not tracked

A non-listed Chinese maker of non-sterile veterinary antibiotic active ingredients and feed additives, selling into the same animal-health raw-material market as BGM's oxytetracycline business.

Wuhan Hvsen Biotechnology Co., Ltd. (武汉回盛生物科技股份有限公司)300871.SZ

Makes veterinary antibiotic active ingredients and the finished animal medicines built on them, competing for the large Chinese pig, poultry and aquaculture producers that also buy BGM's products.

China Animal Husbandry Industry Co., Ltd. (中牧实业股份有限公司)600195.SS

A long-established state-backed supplier of veterinary drugs and veterinary active ingredients to Chinese farms, overlapping with BGM on the animal-medicine side of its pharmaceutical segment.

资产负债表与流动性

营收

$39M

截至最近已公布季度的最近12个月 — 根据每股指标估算

净利润

$-25M

截至最近已公布季度的最近12个月 — 根据每股指标估算

自由现金流

$-5M

股东权益合计

$391M

负债合计

$42M

流动比率

1.24

利息覆盖率

-

债务/EBITDA

-

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$0.49

当前价格

$7.42

安全边际

-1414.5%

公允价值区间

$0.47 - $0.52

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:数据不足,无法计算
现金流折现法(DCF):$0.49
市盈率法(P/E):数据不足,无法计算
格雷厄姆成长公式:数据不足,无法计算
盈利能力价值(EPV):数据不足,无法计算
合理市净率(P/B):数据不足,无法计算
股息折现模型(戈登模型):数据不足,无法计算
P/FFO(运营资金):数据不足,无法计算
周期中段收益:数据不足,无法计算
市销率法(P/S):$0.77

估值指标

市盈率(P/E)

-

ROE

-5.1%

市净率(P/B)

0.13

P/FCF

-

毛利率

16.6%

ROIC

-2.5%

盈利能力雷达图

价值创造(经济护城河)

ROIC

-2.5%

WACC

15.0%

ROIC − WACC

-17.5 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(4)

  • P/B Ratio 0.13
  • Debt/Equity ratio
  • Current Ratio
  • DCF valuation (Undervalued)

未通过(11)

  • EPS shows upward trend
  • Price CAGR -54.62%
  • ROIC -2.5%
  • Gross Margin 16.6%
  • Operating Margin -33.2%
  • Positive Free Cash Flow
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Share Dilution 1435.7%
  • Net Margin Trend -52.6% vs -5.7%
  • Piotroski F-Score 3/9

不可用(12)

  • P/FCF NaN
  • Dividend Payout NaN%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-评分

3/9

存在严重财务隐患

score
criteria

盈利质量

-

低质量:需深入审查会计处理

股权稀释

1435.7%

正在发行新股,稀释所有权

机构持股

该公司暂无机构申报数据。

公司治理

管理团队

姓名职位年龄
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.